233 related articles for article (PubMed ID: 20538611)
21. Lacosamide Inhibition of Nav1.7 Voltage-Gated Sodium Channels: Slow Binding to Fast-Inactivated States.
Jo S; Bean BP
Mol Pharmacol; 2017 Apr; 91(4):277-286. PubMed ID: 28119481
[TBL] [Abstract][Full Text] [Related]
22. mTORC1-dependent translation of collapsin response mediator protein-2 drives neuroadaptations underlying excessive alcohol-drinking behaviors.
Liu F; Laguesse S; Legastelois R; Morisot N; Ben Hamida S; Ron D
Mol Psychiatry; 2017 Jan; 22(1):89-101. PubMed ID: 26952865
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of lacosamide, phenytoin and topiramate on peripheral nerve excitability: An ex vivo electrophysiological study.
Zafeiridou G; Spilioti M; Kagiava A; Krikonis K; Kosmidis EK; Karlovasitou A; Kimiskidis VK
Neurotoxicology; 2016 Jan; 52():57-63. PubMed ID: 26542247
[TBL] [Abstract][Full Text] [Related]
24. VOLTAGE-GATED CALCIUM CHANNELS ARE NOT AFFECTED BY THE NOVEL ANTI-EPILEPTIC DRUG LACOSAMIDE.
Wang Y; Khanna R
Transl Neurosci; 2011 Mar; 2(1):13-22. PubMed ID: 21949591
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of neuronal Na
Peng YS; Wu HT; Lai YC; Chen JL; Yang YC; Kuo CC
Neuropharmacology; 2020 Nov; 179():108266. PubMed ID: 32853658
[TBL] [Abstract][Full Text] [Related]
26. Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosamide and safinamide.
Park KD; Yang XF; Dustrude ET; Wang Y; Ripsch MS; White FA; Khanna R; Kohn H
ACS Chem Neurosci; 2015 Feb; 6(2):316-30. PubMed ID: 25418676
[TBL] [Abstract][Full Text] [Related]
27. Discovery of lacosamide affinity bait agents that exhibit potent voltage-gated sodium channel blocking properties.
Park KD; Yang XF; Lee H; Dustrude ET; Wang Y; Khanna R; Kohn H
ACS Chem Neurosci; 2013 Mar; 4(3):463-74. PubMed ID: 23509982
[TBL] [Abstract][Full Text] [Related]
28. [Lacosamide. A new antiepileptic drug as adjunctive therapy in patients with partial-onset seizures].
Saussele T
Med Monatsschr Pharm; 2008 Oct; 31(10):374-7. PubMed ID: 18972867
[TBL] [Abstract][Full Text] [Related]
29. Effect of lacosamide on ethanol induced conditioned place preference and withdrawal associated behavior in mice: Possible contribution of hippocampal CRMP-2.
Sharma N; Zameer S; Akhtar M; Vohora D
Pharmacol Rep; 2019 Oct; 71(5):804-810. PubMed ID: 31377562
[TBL] [Abstract][Full Text] [Related]
30. Collapsin response mediator protein-2 is a calmodulin-binding protein.
Zhang Z; Majava V; Greffier A; Hayes RL; Kursula P; Wang KK
Cell Mol Life Sci; 2009 Feb; 66(3):526-36. PubMed ID: 19151921
[TBL] [Abstract][Full Text] [Related]
31. CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy.
Piekarz AD; Due MR; Khanna M; Wang B; Ripsch MS; Wang R; Meroueh SO; Vasko MR; White FA; Khanna R
Mol Pain; 2012 Jul; 8():54. PubMed ID: 22828369
[TBL] [Abstract][Full Text] [Related]
32. GSK-3α/β-mediated phosphorylation of CRMP-2 regulates activity-dependent dendritic growth.
Tan M; Ma S; Huang Q; Hu K; Song B; Li M
J Neurochem; 2013 Jun; 125(5):685-97. PubMed ID: 23470087
[TBL] [Abstract][Full Text] [Related]
33. Current understanding of the mechanism of action of the antiepileptic drug lacosamide.
Rogawski MA; Tofighy A; White HS; Matagne A; Wolff C
Epilepsy Res; 2015 Feb; 110():189-205. PubMed ID: 25616473
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylation and mRNA splicing of collapsin response mediator protein-2 determine inhibition of rho-associated protein kinase (ROCK) II function in carcinoma cell migration and invasion.
Morgan-Fisher M; Couchman JR; Yoneda A
J Biol Chem; 2013 Oct; 288(43):31229-40. PubMed ID: 24036111
[TBL] [Abstract][Full Text] [Related]
35. Analgesic ineffectiveness of lacosamide after spinal nerve ligation and its sodium channel activity in injured neurons.
Hagenacker T; Schäfer N; Büsselberg D; Schäfers M
Eur J Pain; 2013 Jul; 17(6):881-92. PubMed ID: 23229998
[TBL] [Abstract][Full Text] [Related]
36. Lacosamide modulates collapsin response mediator protein 2 and inhibits mossy fiber sprouting after kainic acid-induced status epilepticus.
Wang X; Yu Y; Ma R; Shao N; Meng H
Neuroreport; 2018 Nov; 29(16):1384-1390. PubMed ID: 30169428
[TBL] [Abstract][Full Text] [Related]
37. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.
Moutal A; Yang X; Li W; Gilbraith KB; Luo S; Cai S; François-Moutal L; Chew LA; Yeon SK; Bellampalli SS; Qu C; Xie JY; Ibrahim MM; Khanna M; Park KD; Porreca F; Khanna R
Pain; 2017 Dec; 158(12):2301-2319. PubMed ID: 28809766
[TBL] [Abstract][Full Text] [Related]
38. Block of human cardiac sodium channels by lacosamide: evidence for slow drug binding along the activation pathway.
Wang GK; Wang SY
Mol Pharmacol; 2014 May; 85(5):692-702. PubMed ID: 24563546
[TBL] [Abstract][Full Text] [Related]
39. Lacosamide as adjunctive therapy in treatment-resistant epilepsy in childhood.
Gulati P; Cannell P; Ghia T; Bint L; Walsh P; Ghosh S; Nagarajan L
J Paediatr Child Health; 2015 Aug; 51(8):794-7. PubMed ID: 25683595
[TBL] [Abstract][Full Text] [Related]
40. Loss of β1 accessory Na+ channel subunits causes failure of carbamazepine, but not of lacosamide, in blocking high-frequency firing via differential effects on persistent Na+ currents.
Uebachs M; Albus C; Opitz T; Isom L; Niespodziany I; Wolff C; Beck H
Epilepsia; 2012 Nov; 53(11):1959-67. PubMed ID: 23016711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
